ReviewWomen's health (London, England)2008
New treatments for irritable bowel syndrome in women.
Review in Women's health (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Baroreflex mechanisms in Irritable Bowel Syndrome: Part I. Traditional indices.Physiology & behavior · 2016Article
- Sex and disease-related alterations of anterior insula functional connectivity in chronic abdominal pain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Frequency of abnormal fecal biomarkers in irritable bowel syndrome.Global advances in health and medicine · 2014Article
- Prevalence and predictors of irritable bowel syndrome among medical students and interns in King Abdulaziz University, Jeddah.The Libyan journal of medicine · 2013Article
- Sex and gender differences in health. Science & Society Series on Sex and Science.EMBO reports · 2012Article
- Diagnosis and management of IBS.Nature reviews. Gastroenterology & hepatology · 2010Review
- To match or not to match in epidemiological studies--same outcome but less power.International journal of environmental research and public health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The estimated prevalence of irritable bowel syndrome (IBS) in Western countries is 7-15%, with a female:male ratio of 2-2.5:1 in IBS patients who seek healthcare services; however, the female predominance is lower in the general population. IBS has a significant impact on health-related quality of life and is associated with a significant healthcare and economic burden. Management of IBS is comprised of general measures and pharmacologic and nonpharmacologic treatment. However, there are ongoing efforts to find more effective therapeutic approaches. As advancements in the understanding of the pathophysiology of IBS continue to grow, new and effective treatments with novel mechanisms of action that have the potential to improve relief of IBS symptoms over current treatments are likely to be developed. This article provides an overview of current and emerging therapies for IBS and also highlights sex and gender differences in clinical trials and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.